美沙拉嗪栓纳肛联合双歧杆菌三联活菌口服治疗溃疡性结肠炎的临床效果分析

Mesalazine Administered by Rectum plus Oral Bifidobacterium Tripletvaccine Tablet in the Treatment of Ulcerative Colitis:Clinical Effect Analysis

为探讨美沙拉嗪栓纳肛联合双歧杆菌三联活菌口服治疗溃疡性结肠炎(UC)的临床效果,将我院消化内科门诊及住院部收治的85例UC患者作为研究对象,随机数字表法将患者分为观察组(42例)和对照组(43例),对照组予美沙拉嗪栓剂纳肛治疗,观察组在对照组治疗基础上口服双歧杆菌三联活菌胶囊治疗,对比2组治疗有效率及治疗前后临床各观察指标改善情况。结果显示,观察组总有效率(92.86%,39/42)明显高于对照组(79.07%,34/43),差异有统计学意义,P<0.05;治疗后,2组患者疾病活动指数(DAI)评分和内镜评分、丙二醛(MDA)水平和超氧化物歧化酶(SOD)活力较治疗前均得到显著改善,观察组DAI评分、内镜评分、MDA水平均明显低于对照组,SOD活力明显高于对照组,差异有统计学意义,P<0.05。结果表明,美沙拉嗪栓纳肛联合双歧杆菌三联活菌口服治疗UC疗效确切,能够显著降低患者DAI评分和内镜评分,改善患者MDA水平和SOD活力,提高患者生活质量。

To investigate the effect of mezalazine by rectal administration plus oral bifidobacterum triplet- vaccine tablet for treating ulcerative colitis（UC）,85 UC patients who received treatment in author＇s dept. were randomly divided into observation group（ n =42, received above combination therapy） and control one（ n =43,alone rectal administration of mesalazine suppository）, then both group＇s effective rate and all observation indexes improved status were compared.As results,the total effective rate of observation group was significantly higher than control one, there was statistical difference[ （92.86%, 39/42） vs （79.07 %, 34/ 43）, P 〈0.05];patient＇s DAI score,endoscope score,MDA level and SOD activity in both groups were im- proved significantly than before treatment,but the first 3 indexes in observation group were significantly lower than control one（ P〈0.05）;and SOD activity in observation group was significantly higher than control one,there was statistical difference（ P〈 0.05）.Results show that above combination therapy for UC has certain effect, can significantly decrease the score of DAI, and of endoscope, improve MDA level and SOD activity, so that enhance patient＇s quality of life.